NO20045089L - Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser - Google Patents
Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelserInfo
- Publication number
- NO20045089L NO20045089L NO20045089A NO20045089A NO20045089L NO 20045089 L NO20045089 L NO 20045089L NO 20045089 A NO20045089 A NO 20045089A NO 20045089 A NO20045089 A NO 20045089A NO 20045089 L NO20045089 L NO 20045089L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- myopia
- schizophrenia
- treatment
- affective
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 208000001491 myopia Diseases 0.000 title abstract 2
- 230000004379 myopia Effects 0.000 title abstract 2
- 208000004296 neuralgia Diseases 0.000 title abstract 2
- 208000021722 neuropathic pain Diseases 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 208000009205 Tinnitus Diseases 0.000 title 1
- -1 amino alkano phosphonic acids Chemical class 0.000 title 1
- 231100000886 tinnitus Toxicity 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0209889A GB0209889D0 (en) | 2002-04-30 | 2002-04-30 | Organic compounds |
| GB0209886A GB0209886D0 (en) | 2002-04-30 | 2002-04-30 | Organic compounds |
| GB0209887A GB0209887D0 (en) | 2002-04-30 | 2002-04-30 | Organic compounds |
| GB0210371A GB0210371D0 (en) | 2002-05-07 | 2002-05-07 | Organic compounds |
| GB0212760A GB0212760D0 (en) | 2002-05-31 | 2002-05-31 | Organic compounds |
| PCT/EP2003/004466 WO2003092701A2 (en) | 2002-04-30 | 2003-04-29 | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045089L true NO20045089L (no) | 2004-11-23 |
Family
ID=29408096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045089A NO20045089L (no) | 2002-04-30 | 2004-11-23 | Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060293282A1 (de) |
| EP (1) | EP1501518A2 (de) |
| JP (2) | JP2005527600A (de) |
| KR (1) | KR20040101573A (de) |
| CN (1) | CN1649599A (de) |
| BR (1) | BR0309611A (de) |
| CA (1) | CA2482524A1 (de) |
| IL (1) | IL164779A0 (de) |
| MX (1) | MXPA04010816A (de) |
| NO (1) | NO20045089L (de) |
| PL (1) | PL371427A1 (de) |
| TW (1) | TW200403066A (de) |
| WO (1) | WO2003092701A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0310868D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| GB0324542D0 (en) * | 2003-10-21 | 2003-11-26 | Novartis Ag | Organic compounds |
| GB0324541D0 (en) * | 2003-10-21 | 2003-11-26 | Novartis Ag | Organic compounds |
| GB0325175D0 (en) * | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| GB0325172D0 (en) * | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| GB0325390D0 (en) * | 2003-10-30 | 2003-12-03 | Novartis Ag | Organic compounds |
| GB0405034D0 (en) * | 2004-03-05 | 2004-04-07 | Novartis Ag | Organic compounds |
| ITMI20071492A1 (it) | 2007-07-24 | 2009-01-25 | S I I T Srl Servizio Internazi | "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba" |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| GB9400680D0 (en) * | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
| DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| AU4423496A (en) * | 1995-03-14 | 1996-10-02 | Warner-Lambert Company | Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones |
| MY132385A (en) * | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| GB9604400D0 (en) * | 1996-03-01 | 1996-05-01 | Pfizer Ltd | Compounds useful in therapy |
| US6191134B1 (en) * | 1996-06-05 | 2001-02-20 | Warner-Lambert Company | Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists |
| CA2269807C (en) * | 1996-10-24 | 2007-04-10 | Novartis Ag | Substituted aminoalkanephosphonic acids |
| SE508138C2 (sv) * | 1996-12-20 | 1998-08-31 | Ericsson Telefon Ab L M | Metod och anordning för anslutning av elektrisk komponent till kretskort |
| GB9802225D0 (en) * | 1998-02-02 | 1998-04-01 | Cerebrus Ltd | Chemical compounds |
| US6291479B1 (en) * | 1998-12-03 | 2001-09-18 | Alcon Manufacturing, Ltd. | Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases |
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| DE10048969A1 (de) * | 2000-08-23 | 2002-03-14 | Mueller Schwefe Gerhard | Verwendung von Flupirtin zur Tinnitusbehandlung |
| CN1486180A (zh) * | 2000-12-07 | 2004-03-31 | 纽热莫勒丘乐有限公司 | 用nmda受体拮抗物治疗神经精神病紊乱的方法 |
-
2003
- 2003-04-28 TW TW092109911A patent/TW200403066A/zh unknown
- 2003-04-29 KR KR10-2004-7017470A patent/KR20040101573A/ko not_active Ceased
- 2003-04-29 JP JP2004500885A patent/JP2005527600A/ja active Pending
- 2003-04-29 PL PL03371427A patent/PL371427A1/xx not_active Application Discontinuation
- 2003-04-29 EP EP03747434A patent/EP1501518A2/de not_active Withdrawn
- 2003-04-29 BR BR0309611-4A patent/BR0309611A/pt not_active IP Right Cessation
- 2003-04-29 CN CNA038095971A patent/CN1649599A/zh active Pending
- 2003-04-29 CA CA002482524A patent/CA2482524A1/en not_active Abandoned
- 2003-04-29 US US10/512,923 patent/US20060293282A1/en not_active Abandoned
- 2003-04-29 MX MXPA04010816A patent/MXPA04010816A/es unknown
- 2003-04-29 WO PCT/EP2003/004466 patent/WO2003092701A2/en not_active Ceased
-
2004
- 2004-10-21 IL IL16477904A patent/IL164779A0/xx unknown
- 2004-11-23 NO NO20045089A patent/NO20045089L/no not_active Application Discontinuation
-
2009
- 2009-01-22 JP JP2009012152A patent/JP2009137995A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009137995A (ja) | 2009-06-25 |
| WO2003092701A2 (en) | 2003-11-13 |
| PL371427A1 (en) | 2005-06-13 |
| BR0309611A (pt) | 2005-02-09 |
| KR20040101573A (ko) | 2004-12-02 |
| MXPA04010816A (es) | 2005-03-07 |
| CA2482524A1 (en) | 2003-11-13 |
| WO2003092701A3 (en) | 2004-04-08 |
| EP1501518A2 (de) | 2005-02-02 |
| US20060293282A1 (en) | 2006-12-28 |
| JP2005527600A (ja) | 2005-09-15 |
| IL164779A0 (en) | 2005-12-18 |
| TW200403066A (en) | 2004-03-01 |
| CN1649599A (zh) | 2005-08-03 |
| AU2003232224A1 (en) | 2003-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE457171T1 (de) | Kombinationstherapie substituierter oxazolidinone | |
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| ATE407676T1 (de) | Topoisomerasehemmern zur behandlung von chirurgischen verklebungen | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
| ATE427114T1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen | |
| DE60101265D1 (de) | Behandlung von augenschmerzen | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE311226T1 (de) | Die glycin-betain für seine antithrombotische verwendung | |
| DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| NO20045089L (no) | Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
| DE69932922D1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| DE602004003173D1 (de) | Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung | |
| DE60215219D1 (de) | Verwendung von darifenacin zur behandlung des harndrangs | |
| DK1235573T3 (da) | Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme | |
| ATE464042T1 (de) | Verwendung von neboglamine zur behandlung von schizophrenie | |
| HK1073254A (en) | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |